Fapdol325 mg+37.5 mg

Fapdol is a fixed-dose combination analgesic containing a non-opioid analgesic/antipyretic (paracetamol) and a centrally acting synthetic opioid analgesic (tramadol). It is indicated for the following:

Established/Approved Uses

• Management of moderate to moderately severe pain in adults, such as postoperative pain, musculoskeletal pain, dental pain, and pain following minor trauma, when combined use of an opioid and a non-opioid analgesic is appropriate.
• Short-term (five days or less) management of acute pain, particularly when a rapid onset combined with sustained analgesia is required and the potential benefits outweigh the risks of opioid use.

Important Note on Use

Fapdol is intended for short-term, as-needed use at the lowest effective dose for the shortest duration consistent with the treatment goals of the patient, because of the opioid component's risk of misuse, abuse, addiction, and respiratory depression, and the paracetamol component's risk of hepatotoxicity with prolonged or excessive use.

Each tablet of Paracetamol + Tramadol Hydrochloride typically contains:

• Paracetamol (Acetaminophen) 325 mg — non-opioid analgesic and antipyretic.
• Tramadol Hydrochloride 37.5 mg — centrally acting synthetic opioid analgesic.

Other strengths and combinations may be marketed in different countries; always check the product label for the exact composition of the specific brand dispensed.

Fapdol is an orally administered fixed-dose combination medicine that pairs two analgesics with complementary mechanisms of action to provide effective relief of moderate to moderately severe pain. Paracetamol provides a rapid, non-opioid analgesic and antipyretic effect, while tramadol contributes an opioid-mediated analgesic effect along with monoaminergic (serotonin and norepinephrine reuptake inhibition) activity. This dual mechanism allows Fapdol to provide effective pain relief, often at lower doses of each individual component than would be required if either agent were used alone, which may help reduce the incidence of certain dose-related adverse effects.

Fapdol is available as film-coated tablets and is used under medical supervision, typically for short courses of treatment.

Fapdol belongs to the therapeutic class of combination analgesics (non-opioid + opioid analgesic combinations). It combines paracetamol (a para-aminophenol derivative analgesic/antipyretic) with tramadol (a centrally acting synthetic opioid analgesic of the aminocyclohexanol class). Because it contains an opioid component, Fapdol is classified and regulated as a controlled substance in many jurisdictions.

Paracetamol + Tramadol Hydrochloride combines two agents with distinct but complementary pharmacological mechanisms:

Paracetamol

The precise mechanism of paracetamol's analgesic and antipyretic action is not fully established but is believed to involve central inhibition of prostaglandin synthesis and modulation of the descending serotonergic pathways, with minimal peripheral anti-inflammatory activity and negligible effect on platelet function or gastric mucosa compared to NSAIDs.

Tramadol

Tramadol is a centrally acting analgesic with two complementary mechanisms: (1) low-affinity binding of the parent compound and its active metabolite (O-desmethyltramadol) to μ-opioid receptors, and (2) inhibition of neuronal reuptake of norepinephrine and serotonin, which enhances descending inhibitory pain pathways. Tramadol is metabolized in the liver, partly via CYP2D6 to its more potent active metabolite, and via CYP3A4; genetic variation in CYP2D6 activity can affect individual response.

Following oral administration, both components are well absorbed, with peak plasma concentrations typically reached within 1-2 hours; onset of analgesia generally occurs within 30-60 minutes.

Fapdol tablets should be swallowed whole with a glass of water and may be taken with or without food. Do not crush, chew, or break the tablets, as this may alter the release characteristics and increase the risk of adverse effects. Doses should be spaced at least 4-6 hours apart, and the total daily dose must not exceed the maximum recommended limit.

Fapdol has several clinically significant drug interactions related to both its opioid (tramadol) and non-opioid (paracetamol) components:

• Monoamine oxidase inhibitors (MAOIs): Concomitant use or use within 14 days of an MAOI is contraindicated (see Contraindications) due to risk of serotonin syndrome and seizures.
• Serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants, triptans, other serotonergic agents): Increased risk of serotonin syndrome; combined use requires caution and close monitoring.
• CNS depressants (benzodiazepines, sedatives, other opioids, general anesthetics, alcohol): Additive risk of profound sedation, respiratory depression, coma, and death; avoid concurrent use unless no alternative exists, and use the lowest effective doses for the shortest duration if combined.
• CYP2D6 and CYP3A4 inhibitors (e.g., quinidine, certain antifungals, certain antidepressants): May alter tramadol metabolism, increasing risk of seizures, serotonin syndrome, or reduced analgesic effect.
• Drugs that lower seizure threshold: Increased risk of seizures when combined with tramadol.
• Warfarin and other coumarin anticoagulants: Paracetamol may potentiate the anticoagulant effect with regular use; monitor INR if combined.
• Other paracetamol-containing products: Concurrent use increases the risk of hepatotoxicity from cumulative paracetamol exposure; avoid combining.

The most commonly reported adverse effects of Fapdol include:

• Nausea, vomiting, constipation, dry mouth, abdominal pain, dyspepsia
• Dizziness, drowsiness, headache, tremor, asthenia/fatigue
• Sweating, pruritus, rash
• Anxiety, insomnia, confusion (particularly in elderly patients)

Less common but serious adverse effects include seizures, serotonin syndrome, respiratory depression, severe allergic reactions (including anaphylaxis and angioedema), and hepatotoxicity (with overdose or excessive cumulative paracetamol intake). See Precautions and Warnings for details on these serious risks.

Pregnancy: Fapdol is not recommended during pregnancy, including labor and delivery, because of the opioid (tramadol) component's risk of neonatal respiratory depression and neonatal opioid withdrawal syndrome with prolonged use during pregnancy. It should be used only if the potential benefit justifies the potential risk to the fetus, and only under close medical supervision; consult a physician before use in pregnancy.

Lactation: Both paracetamol and tramadol pass into breast milk. Fapdol is not recommended for breastfeeding mothers due to the risk of serious adverse reactions, including excess sedation and respiratory depression, in the breastfed infant from the tramadol component; this risk may be higher in infants of mothers who are ultra-rapid metabolizers of CYP2D6. If use cannot be avoided, the infant should be monitored closely, and a physician should be consulted.

Hepatotoxicity (Paracetamol Component)

Serious, sometimes fatal, hepatotoxicity has been associated with paracetamol use, particularly at doses exceeding 4000 mg/day, with chronic alcohol use, pre-existing liver disease, or when combined with other paracetamol-containing products. Patients must be counseled not to take any other product containing paracetamol/acetaminophen while using Fapdol.

Seizure Risk (Tramadol Component)

Seizures have been reported with tramadol use, particularly at doses above the recommended range, and with concurrent use of SSRIs, tricyclic antidepressants, other opioids, MAOIs, neuroleptics, or other drugs that reduce the seizure threshold, and in patients with epilepsy or other seizure risk factors.

Serotonin Syndrome

Fapdol can cause a potentially life-threatening serotonin syndrome, especially when co-administered with other serotonergic drugs (see Interactions). Signs include agitation, hallucinations, tachycardia, hyperthermia, exaggerated reflexes, tremor, and gastrointestinal symptoms; discontinue immediately and seek medical attention if suspected.

Respiratory Depression

Serious, life-threatening respiratory depression may occur, especially in elderly, cachectic, or debilitated patients, or when combined with other CNS depressants including alcohol. Use caution and monitor closely, particularly at treatment initiation and dose changes.

Dependence, Abuse, and Withdrawal

Fapdol contains tramadol, an opioid with potential for misuse, abuse, and addiction, even at recommended doses. Prolonged use may lead to physical dependence and a withdrawal syndrome on abrupt discontinuation; dose should be tapered gradually when stopping after extended use. Use the lowest effective dose for the shortest duration necessary.

General

May impair mental and/or physical abilities required for driving or operating machinery; avoid alcohol. Use with caution in patients with head injury, increased intracranial pressure, biliary tract disease, or a history of substance use disorder. Do not stop, extend, skip doses, or share this medicine with others without medical advice.

Overdose of Fapdol is a medical emergency due to the combined toxicity of both components. Paracetamol overdose can cause severe, potentially fatal hepatotoxicity, which may not be apparent for 24-48 hours; early symptoms may be absent or nonspecific (nausea, vomiting, malaise), followed by signs of liver injury. Tramadol overdose can cause seizures, severe respiratory depression, extreme drowsiness progressing to coma, miosis, hypotension, cardiac arrest, and death.

In case of suspected overdose, seek immediate emergency medical attention or contact a poison control center right away, even if the patient appears well, because paracetamol-related liver damage may not be immediately apparent and requires prompt evaluation and treatment (such as N-acetylcysteine therapy) to prevent serious harm. Do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Fapdol is contraindicated in children under 12 years of age, and in patients under 18 years following tonsillectomy and/or adenoidectomy, due to the risk of life-threatening respiratory depression from the tramadol component. Use in patients aged 12-18 years who have other risk factors for respiratory depression (e.g., obstructive sleep apnea, obesity, severe pulmonary disease) is not recommended. Safety and efficacy in children under 12 years have not been established.

Geriatric Use

Elderly patients (particularly those over 75 years) may require lower doses and longer dosing intervals due to reduced clearance of both components and increased sensitivity to CNS and respiratory depressant effects; use with caution and close monitoring.

Renal Impairment

Dose adjustment (reduced dose, extended interval) is required in patients with creatinine clearance below 30 mL/min; see Dosage and Administration.

Hepatic Impairment

Use is generally not recommended in patients with hepatic impairment, particularly severe impairment, due to increased risk of hepatotoxicity and altered tramadol clearance.

Fapdol is intended for short-term use only. For acute pain, treatment is generally limited to 5 days or less. For other indications of moderate to moderately severe pain, Fapdol should be used at the lowest effective dose for the shortest duration consistent with individual patient treatment goals, due to the risks of opioid dependence/misuse and cumulative paracetamol-related hepatotoxicity with prolonged use. Continued need for therapy beyond a few days should be reassessed by a physician.

Paracetamol + Tramadol Hydrochloride falls under the drug classes: Analgesic combination (non-opioid + opioid); specifically, paracetamol (acetaminophen) is classified as a non-opioid analgesic/antipyretic, and tramadol hydrochloride is classified as a centrally-acting synthetic opioid analgesic (Schedule/Controlled substance in many countries).

Paracetamol + Tramadol Hydrochloride acts through a dual and complementary mechanism. Paracetamol is believed to act primarily via central inhibition of prostaglandin synthesis and modulation of descending serotonergic pain pathways, providing analgesic and antipyretic effects with minimal peripheral anti-inflammatory activity. Tramadol acts as a weak agonist at μ-opioid receptors while also inhibiting the reuptake of norepinephrine and serotonin in the central nervous system, which enhances descending inhibition of pain signals. This combination provides synergistic analgesia, allowing effective pain control often with lower doses of each agent than would be needed alone.

Category C

Fapdol is contraindicated in children under 12 years of age and in patients under 18 years following tonsillectomy and/or adenoidectomy, because of the risk of life-threatening or fatal respiratory depression associated with the tramadol component, particularly in those who are ultra-rapid metabolizers of CYP2D6. Use is not recommended in patients aged 12 to 18 years who have other risk factors for respiratory depression, such as obstructive sleep apnea, obesity, or severe pulmonary disease. Safety and efficacy of Fapdol in the pediatric population under 12 years have not been established, and it should never be used in this age group.